TABLE 1.

Association of Pretreatment, Surgery and Pathology Variables with Adjuvant Therapy

Variable	No AT (n=95, 42%)		AT (n=129, 58%)		p
	N	%	N	%
	Pretreatment Data
Age (mean and SD)*	66	10	64	12	0.180
Male	53	56	82	64	0.240
Race					0.162
Caucasian	73	77	105	82
Other	22	23	24	19
ASA					0.432
1	1	1	1	1
2	23	29	42	38
3	50	64	66	59
4	4	5	2	2
Comorbiditiesa					0.141
Yes	63	66	56	43
No	32	34	73	57
Neo-adjuvant Therapy	6	6	4	3	0.250
	Operative and Pathology Data
Diagnostic Laparoscopy	19	20	16	`1	0.128
Type of Operation					0.017
BD Resection Only	16	17	35	28
Right Hepatectomy and BD	17	18	8	6
Left Hepatectomy and BD	16	17	35	28
Extended Right Hepatectomy and BD	20	21	16	13
Extended Left Hepatectomy and BD	6	6	12	9
Right Trisectionectomy and BD	10	10	12	9
Left Trisectionectomy and BD	9	10	9	7
Method of Operationa					0.177
Open	93	98	128	99
Laparoscopic	0	0	1	1
Converted to Open	2	2	0	0
Frozen Section +	24	29	49	46	0.015
Intraoperative RBCs	45	54	35	30	0.001
R Status					0.012
R0	71	75	77	60
R1	24	25	52	40
AJCC 7th. ed. T Stage18					0.803
T1	29	31	36	28
T2	47	49	72	56
T3	15	16	17	13
T4	4	4	4	3
Grade of Differentiation					0.237
Well	12	15	25	20
Moderate	53	65	69	55
Poor	15	19	32	25
Undifferentiated	1	1	0	0
LVI	27	34	49	45	0.124
LN Positive	17	20	55	49	<0.001
	Postoperative Data
Readmission ≤ 90 Days	24	41	28	32	0.923
Recurrence Locationb					0.198
Local	12	43	15	24
Distant	11	39	31	50
Local + Distant	5	18	16	26

Abbreviations: AT, adjuvant therapy; SD, standard deviation; ASA, American Society of Anesthesiologists classification system; BD, bile duct; R status, resection status; AJCC, American Joint Committee on Cancer; LVI, lymphovascular invasion; LN, lymph node.

^*For Age: columns n and % signify mean and standard deviation, respectively

^aComorbidities determined via chart review, as discussed in methods section

^b% reflects percentage of the total number of patients that had a recurrence